
Karolinska Development Investor Relations Material
Latest events

Q2 2025
29 Aug, 2025

Q1 2025
30 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Karolinska Development
Access all reports
Karolinska Development AB is a Sweden-based investment company that plays a significant role in the biotechnology sector. It is primarily engaged in providing capital, developing, and commercializing biotechnological products. The company's activities span a broad range of medical and therapeutic areas, including oncology, infections and wound healing, women’s health, cardiovascular and hematology, as well as medical equipment and diagnostics. Karolinska Development AB showcases a diverse portfolio that comprises investments in pharmaceutical research and development, healthcare technology, gene research and development, drug delivery technologies, and life sciences tools, among others. Founded in 2003 and with a modest team, the company focuses on fostering innovation and advancing the development of new treatments and medical solutions. The company is headquartered in Solna, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
KDEV
Country
🇸🇪 Sweden